Skip to content
Live
Trending storyPast story

OpenAI acquires bio-tech AI startup Orchestra Bio

2 reports2 outlets29 days agoUpdate

The story so far

No overview yet — start with the coverage timeline below.

Coverage timeline

Follow the coverage to see every side of the story.

21 Oct
  1. The Decoder
    OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

    OpenAI acquired Orchestra Bio, a startup that helps pharmaceutical teams coordinate drug development, and integrated it into the life sciences platform Rosalind. Orchestra's agents are used to track trials, flag timelines affected by issues like production batch failures, and provide follow-up options. OpenAI states that developing a drug in the US takes an average of 10 to 15 years, and the transaction amount was not disclosed.